Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?
cancer core length
cribriform pattern
multiparametric MRI
prostate cancer
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
08
05
2023
accepted:
24
07
2023
medline:
2
11
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
ppublish
Résumé
Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investigate whether the CBFM pattern containing prostate cancers (PCa) were associated with false negative magnetic resonance imaging (MRI) and determine the association between MRI and histopathological disease burden. Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively queried for the presence of CBFM pattern at biopsy. Biopsy cores and lesions were categorized as follows: C0 = benign, C1 = PCa with no CBFM pattern, C2 = PCa with CBFM pattern. Correlation between cancer core length (CCL) and measured MRI lesion dimension were assessed using a modified Pearson correlation test for clustered data. Differences between the biopsy core groups were assessed with the Wilcoxon-signed rank test with clustering. Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (1149 C0, 272 C1, 151 C2) and 736 MRI-targeted biopsy cores (253 C0, 272 C1, 211 C2). Of the 131 patients with confirmed CBFM pathology, targeted biopsy (TBx) alone identified CBFM in 76.3% (100/131) of patients and detected PCa in 97.7% (128/131) patients. SBx biopsy alone detected CBFM in 61.1% (80/131) of patients and PCa in 90.8% (119/131) patients. TBx and SBx had equivalent detection in patients with smaller prostates (p = 0.045). For both PCa lesion groups there was a positive and significant correlation between maximum MRI lesion dimension and CCL (C1 lesions: p < 0.01, C2 lesions: p < 0.001). There was a significant difference in CCL between C1 and C2 lesions for T2 scores of 3 and 5 (p ≤ 0.01, p ≤ 0.01, respectively) and PI-RADS 5 lesions (p ≤ 0.01), with C2 lesions having larger CCL, despite no significant difference in MRI lesion dimension. The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger cancer yield on biopsy. Proper staging and planning of therapeutic interventions is reliant on accurate mpMRI estimation. Special considerations should be taken for patients with CBFM pattern on prostate biopsy.
Sections du résumé
BACKGROUND
Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investigate whether the CBFM pattern containing prostate cancers (PCa) were associated with false negative magnetic resonance imaging (MRI) and determine the association between MRI and histopathological disease burden.
METHODS
Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively queried for the presence of CBFM pattern at biopsy. Biopsy cores and lesions were categorized as follows: C0 = benign, C1 = PCa with no CBFM pattern, C2 = PCa with CBFM pattern. Correlation between cancer core length (CCL) and measured MRI lesion dimension were assessed using a modified Pearson correlation test for clustered data. Differences between the biopsy core groups were assessed with the Wilcoxon-signed rank test with clustering.
RESULTS
Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (1149 C0, 272 C1, 151 C2) and 736 MRI-targeted biopsy cores (253 C0, 272 C1, 211 C2). Of the 131 patients with confirmed CBFM pathology, targeted biopsy (TBx) alone identified CBFM in 76.3% (100/131) of patients and detected PCa in 97.7% (128/131) patients. SBx biopsy alone detected CBFM in 61.1% (80/131) of patients and PCa in 90.8% (119/131) patients. TBx and SBx had equivalent detection in patients with smaller prostates (p = 0.045). For both PCa lesion groups there was a positive and significant correlation between maximum MRI lesion dimension and CCL (C1 lesions: p < 0.01, C2 lesions: p < 0.001). There was a significant difference in CCL between C1 and C2 lesions for T2 scores of 3 and 5 (p ≤ 0.01, p ≤ 0.01, respectively) and PI-RADS 5 lesions (p ≤ 0.01), with C2 lesions having larger CCL, despite no significant difference in MRI lesion dimension.
CONCLUSIONS
The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger cancer yield on biopsy. Proper staging and planning of therapeutic interventions is reliant on accurate mpMRI estimation. Special considerations should be taken for patients with CBFM pattern on prostate biopsy.
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1519-1528Informations de copyright
Published 2023. This article is a U.S. Government work and is in the public domain in the USA.
Références
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763
Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76(3):340-351. doi:10.1016/j.eururo.2019.02.033
Johnson DC, Raman SS, Mirak SA, et al. Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging. Eur Urol. 2019;75(5):712-720. doi:10.1016/j.eururo.2018.11.031
Houlahan KE, Salmasi A, Sadun TY, et al. Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer. Eur Urol. 2019;76(1):18-23. doi:10.1016/j.eururo.2018.12.036
Downes MR, Gibson E, Sykes J, Haider M, van der Kwast TH, Ward A. Determination of the association between T2-weighted MRI and gleason sub-pattern: a proof of principle study. Academic Radiol. 2016;23(11):1412-1421. doi:10.1016/j.acra.2016.07.013
Norris JM, Carmona Echeverria LM, Bott SRJ, et al. What type of prostate cancer is systematically overlooked by multiparametric magnetic resonance imaging? An analysis from the PROMIS cohort. Eur Urol. 2020;78(2):163-170. doi:10.1016/j.eururo.2020.04.029
Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2017;41(4):e1-e7. doi:10.1097/PAS.0000000000000820
Russo GI, Soeterik T, Puche-Sanz I, et al. Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. Published online October 10, 2022:1-9. https://www.nature.com/articles/s41391-022-00600-y
Elfandy H, Armenia J, Pederzoli F, et al. Genetic and epigenetic determinants of aggressiveness in cribriform carcinoma of the prostate. Mol Cancer Res. 2019;17(2):446-456. doi:10.1158/1541-7786.MCR-18-0440
Böttcher R, Kweldam CF, Livingstone J, et al. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. BMC Cancer. 2018;18(1):8. doi:10.1186/s12885-017-3976-z
van Leenders GJLH, Kweldam CF, Hollemans E, et al. Improved prostate cancer biopsy grading by incorporation of invasive cribriform and intraductal carcinoma in the 2014 grade groups. Eur Urol. 2020;77(2):191-198. doi:10.1016/j.eururo.2019.07.051
Kweldam CF, van Leenders GJ, van der Kwast T. Grading of prostate cancer: a work in progress. Histopathology. 2019;74(1):146-160. doi:10.1111/his.13767
van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol. 2020;44(8):e87-e99. doi:10.1097/PAS.0000000000001497
van der Kwast TH, van Leenders GJ, Berney DM, et al. ISUP consensus definition of cribriform pattern prostate cancer. Am J Surg Pathol. 2021;45(8):1118-1126. doi:10.1097/PAS.0000000000001728
Hollemans E, Verhoef EI, Bangma CH, et al. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Mod Pathol. 2019;32(1):139-146. doi:10.1038/s41379-018-0157-9
Okubo Y, Sato S, Hasegawa C, et al. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores. Hum Pathol. 2023;135:99-107. doi:10.1016/j.humpath.2023.01.008
Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP. Impact of gleason subtype on prostate cancer detection using multiparametric magnetic resonance imaging: correlation with final histopathology. J Urol. 2017;198(2):316-321. doi:10.1016/j.juro.2017.01.077
Arslan A, Alis D, Tuna MB, Sağlıcan Y, Kural AR, Karaarslan E. The visibility of prostate cancer concerning underlying histopathological variances: a single-center multiparametric magnetic resonance imaging study. Eur J Radiol. 2021;141:109791. doi:10.1016/j.ejrad.2021.109791
Kazan O, Gunduz N, Kir G, et al. The cribriform morphology impairs Gleason 7 prostate cancer lesion detection on multiparametric magnetic resonance imaging. Prostate. 2023;83(4):331-339. doi:10.1002/pros.24465
Jiang Y, Lee M-LT, He X, Rosner B, Yan J. Wilcoxon rank-based tests for clustered data with R package clusrank. J Stat Softw. 2020;96:1-26. doi:10.18637/jss.v096.i06
Shih JH, Fay MP. Pearson's chi-square test and rank correlation inferences for clustered data: Pearson's Chi-square test and rank correlation inferences for clustered data. Biometrics. 2017;73(3):822-834. doi:10.1111/biom.12653
Ericson KJ, Wu SS, Lundy SD, Thomas LJ, Klein EA, McKenney JK. Diagnostic accuracy of prostate biopsy for detecting cribriform gleason pattern 4 carcinoma and intraductal carcinoma in paired radical prostatectomy specimens: implications for active surveillance. J Urol. 2020;203(2):311-319. doi:10.1097/JU.0000000000000526
Prendeville S, Gertner M, Maganti M, et al. Role of magnetic resonance imaging targeted biopsy in detection of prostate cancer harboring adverse pathological features of intraductal carcinoma and invasive cribriform carcinoma. J Urol. 2018;200(1):104-113. doi:10.1016/j.juro.2018.01.081
Truong M, Feng C, Hollenberg G, et al. A comprehensive analysis of cribriform morphology on magnetic resonance imaging/ultrasound fusion biopsy correlated with radical prostatectomy specimens. J Urol. 2018;199(1):106-113. doi:10.1016/j.juro.2017.07.037
Ahdoot M, Wilbur AR, Reese SE, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382(10):917-928. doi:10.1056/NEJMoa1910038
Masoomian M, Downes MR, Sweet J, et al. Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. Histopathology. 2019;74(3):474-482. doi:10.1111/his.13747